This meeting is supported by:
PROGRAMME
| 08.30 - 09.25 | Arrival, registration and coffee |
| 09.25 - 09.30 | Welcome and introduction |
| Session 1 | |
| 09.30 - 10.10 | 1-1 From Ligases to Molecular Glues - Strategies to Discover Novel Molecular Glues Markus Queisser, Director, Novel Modalities Group, GSK |
| 10.10 - 10.50 | 1-2 Multimodal screening strategy for discovery of novel cereblon-directing molecular glue degraders and neosubstrates Zoran Rankovic, Director, CPD ICR |
| 10.50 - 11.10 | Coffee break and exhibitors |
| Session 2 | |
| 11.10 - 11.50 | 2-1 Cooperativity: How to Discover Molecular Glues de Novo using Biophysics Pim de Vink, ZoBio |
| 11.50 - 12.30 | 2-2 Degradation of BRD9 by a novel “targeted glue” Marta Carrara, Amphista |
| 12.30 - 13.30 | Lunch break and exhibitors |
| Session 3 | |
| 13.30 - 14.10 | 3-1 Using native mass spectrometry in the search for novel molecular glues Aneika Leney, University of Birmingham, Group Leader |
| 14.10 - 14.50 | 3-2 Sticking together: Merck Health approach to molecular glue discovery Ingo Kober, Director Molecular Pharmacology Group, Merck |
| 14.50 - 15.10 | Coffee break and exhibitors
|
| Session 4 | |
| 15.10 - 15.50 | 4-1 Converging Mechanisms between a Molecular Glue Degrader and Neomorphic Cancer Mutations in an E3 ligase Brian Liau, Group Leader, Harvard University |
| 15.50 - 16.30 | 4-2 Unveiling the hidden interactome of CRBN molecular glues with chemoproteomics Katherine Donovan, Dana Farber |
| 16.30 - 17.10 | 4-3 Exploring new opportunities in induced proximity Ed Tate, Imperial College London |
| 17.10 | Closing remarks and drinks reception |